eli lilly's tirzepatide is the leader in weight loss sector 'Miracle' drugs could remake industry Lilly's weight-loss drug reduces sleep
Description
Roughly 5 to 8% of patients in clinical trials discontinued due to side effects
In conclusion, while both semaglutide and tirzepatide offer significant benefits in managing type 2 diabetes and weight loss, the decision to switch between these medications should be based on individual patient needs and guided by healthcare provider expertise
And get your next appointment on the calendar, so you can stick to a plan of continued care
Studies have shown a reduction in major cardiovascular events
Both outcomes were controlled for type 1 error rate in both trials
